Kathleen M Buchheit1, Kathryn E Hulse2. 1. Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. 2. Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Current Affiliation: Type 2 Inflammation and Fibrosis Cluster, Immunology and Inflammation Therapeutic Area, Sanofi, Cambridge, Massachusetts. Electronic address: katie.hulse@sanofi.com.
Abstract
OBJECTIVE: Local activation of B cells and antibody production are important for protective and pathogenic immune responses. Furthermore, there is evidence that local activation of B cells and antibody production are important for pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP) and a severe subset of CRSwNP, aspirin-exacerbated respiratory disease (AERD). This review summarizes these findings and the potential role of B cells and antibodies in disease pathogenesis. DATA SOURCES: Published literature from PubMed searches. STUDY SELECTIONS: Studies relevant to B cell development and the roles of B cells and antibodies in the pathogenesis of CRSwNP and AERD. RESULTS: Formation of tertiary lymphoid structures plays a key role in the local activation of B cells and antibody production. This process is important for fighting infections, but it also contributes to autoimmune disease. Furthermore, there is evidence to support a role for local B cell activation and antibody production in a variety of allergic diseases. Nasal polyp tissues from patients with CRSwNP and AERD have elevated levels of activated B cell subsets and locally produced antibodies. These locally produced antibodies may contribute to disease pathogenesis in a variety of ways, including activation of innate effector cells, whereas locally activated B cells may contribute to pathogenesis through the activation of T cells. CONCLUSION: More studies are needed to determine the role of B cells and antibodies in driving disease in these patients. However, targeting the processes that drive local B cell activation and antibody production may provide new therapeutic approaches and could help to reduce chronic inflammation.
OBJECTIVE: Local activation of B cells and antibody production are important for protective and pathogenic immune responses. Furthermore, there is evidence that local activation of B cells and antibody production are important for pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP) and a severe subset of CRSwNP, aspirin-exacerbated respiratory disease (AERD). This review summarizes these findings and the potential role of B cells and antibodies in disease pathogenesis. DATA SOURCES: Published literature from PubMed searches. STUDY SELECTIONS: Studies relevant to B cell development and the roles of B cells and antibodies in the pathogenesis of CRSwNP and AERD. RESULTS: Formation of tertiary lymphoid structures plays a key role in the local activation of B cells and antibody production. This process is important for fighting infections, but it also contributes to autoimmune disease. Furthermore, there is evidence to support a role for local B cell activation and antibody production in a variety of allergic diseases. Nasal polyp tissues from patients with CRSwNP and AERD have elevated levels of activated B cell subsets and locally produced antibodies. These locally produced antibodies may contribute to disease pathogenesis in a variety of ways, including activation of innate effector cells, whereas locally activated B cells may contribute to pathogenesis through the activation of T cells. CONCLUSION: More studies are needed to determine the role of B cells and antibodies in driving disease in these patients. However, targeting the processes that drive local B cell activation and antibody production may provide new therapeutic approaches and could help to reduce chronic inflammation.
Authors: Juan E Moyron-Quiroz; Javier Rangel-Moreno; Kim Kusser; Louise Hartson; Frank Sprague; Stephen Goodrich; David L Woodland; Frances E Lund; Troy D Randall Journal: Nat Med Date: 2004-08-15 Impact factor: 53.440
Authors: S Feldman; R Kasjanski; J Poposki; D Hernandez; J N Chen; J E Norton; L Suh; R G Carter; W W Stevens; A T Peters; R C Kern; D B Conley; B K Tan; S Shintani-Smith; K C Welch; L C Grammer; K E Harris; A Kato; R P Schleimer; K E Hulse Journal: Clin Exp Allergy Date: 2017-01-26 Impact factor: 5.018
Authors: Frédéric Perros; Peter Dorfmüller; David Montani; Hamida Hammad; Wim Waelput; Barbara Girerd; Nicolas Raymond; Olaf Mercier; Sacha Mussot; Sylvia Cohen-Kaminsky; Marc Humbert; Bart N Lambrecht Journal: Am J Respir Crit Care Med Date: 2011-11-22 Impact factor: 21.405
Authors: Kathleen M Buchheit; Daniel F Dwyer; Jose Ordovas-Montanes; Howard R Katz; Erin Lewis; Marko Vukovic; Juying Lai; Lora G Bankova; Neil Bhattacharyya; Alex K Shalek; Nora A Barrett; Joshua A Boyce; Tanya M Laidlaw Journal: J Allergy Clin Immunol Date: 2020-03-19 Impact factor: 10.793
Authors: Jill S Jeffe; Sudarshan Seshadri; Kevin J Hamill; Julia He Huang; Roderick Carter; Lydia Suh; Kathryn E Hulse; James Norton; David B Conley; Rakesh K Chandra; Robert C Kern; Jonathan C R Jones; Robert P Schleimer; Bruce K Tan Journal: Laryngoscope Date: 2013-09 Impact factor: 3.325
Authors: Jose Ordovas-Montanes; Daniel F Dwyer; Sarah K Nyquist; Kathleen M Buchheit; Marko Vukovic; Chaarushena Deb; Marc H Wadsworth; Travis K Hughes; Samuel W Kazer; Eri Yoshimoto; Katherine N Cahill; Neil Bhattacharyya; Howard R Katz; Bonnie Berger; Tanya M Laidlaw; Joshua A Boyce; Nora A Barrett; Alex K Shalek Journal: Nature Date: 2018-08-22 Impact factor: 49.962